DuchenneMuscular Dystrophy (DMD) Treatment Market - Global Industry Insights,Trends, Outlook, and Opportunity Analysis, 2018-2026
Duchenne muscular dystrophy (DMD)is a genetic disorder characterized by progressive muscle degeneration andweakness. DMD is caused due to alteration in gene sequence coding fordystrophin protein, which is present the muscle. It is a rare muscle diseasewhich majorly affects males. The symptoms includes intellectual disability,muscle weakness and, difficulty in walking and breathing. Congestive heart failure, mental impairment,pneumonia or respiratory failure are some of the complications of this disease.The treatment is available to control or reduce the signs and symptoms as DMDis not curable. Steroid drugs are used to control the symptoms of duchennemuscular dystrophy. Stem cell therapy and gene therapy could be used for treatmentof this disease in future.
Growing investments in theresearch and development, to find out effective treatment for DMD is drivingthe growth of duchenne muscular dystrophy (DMD) treatment market
According to the reports ofCenters for Disease Control and prevention (CDC) 2007, 349 out of 2.37 millionmales in the United States were reported to be suffering from DMD. Whereas in2019, 349 new cases of DMD were reported.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/898
Increasing incidences of DMD andrequirement for its treatment is driving the growth of duchenne musculardystrophy treatment market. Various organizations are involved in spreadingawareness and investing in research and development to find the effectivetreatment for this disease, which is contributing to the growth of duchennemuscular dystrophy treatment market. For instance, Muscular DystrophyAssociation (MDA), U.S. invests 75000 USD in research and development to findout the treatment for duchenne muscular dystrophy and the association funds morethan 150 care centers, health care facility centers, and hospitals across U.S.and other countries. Moreover, other factors, such as constant research on stemcell therapy, gene therapy, and exon skipping drugs for the treatment of DMD isexpected to propel the growth of DMD treatment market. However, majorrestraints hampering the growth of duchenne muscular dystrophy treatment marketare, low seeking rate due to prognosis and late diagnosis of this disease.
Rising hospitalization for DMD isthe factor helping the hospital segment to hold the maximum share in duchennemuscular dystrophy (DMD) treatment market
Growing patient population inNorth America and Europe is the factor contributing to the growth of duchennemuscular dystrophy (DMD) treatment market in these regions
Regional segmentation of Duchennemuscular dystrophy (DMD) treatment market by Coherent Market Insights comprisesof North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.North America dominates in the duchenne muscular dystrophy treatment market,due well-established healthcare facilities in this region.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/duchenne-muscular-dystrophy-treatment-market-898
Europe contributes to the growthof duchenne muscular dystrophy treatment market followed by North America, dueto high rate of affected population in this region. For instance, according toCenter for Disease Control and Prevention (CDC), in North England, 233 out of1.49 million male patients were reported for DMD or other muscular dystrophycases in 2009.
Key players are involved in theresearch and development of novel drug therapy for the treatment of duchennemuscular dystrophy (DMD)
Key players operating duchennemuscular dystrophy (DMD) treatment market includes SUMMIT Therapeutics Plc.,PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics,Pfizer Incorporated, Pharmacia & Upjohn LLC, and others. Major industryplayers are involved in the research and development of novel drugs fortreatment, and strategies such as collaboration and partnership are adopted bycompanies to hold the major share in the duchenne muscular dystrophy (DMD)treatment market. For instance, PTC Therapeutics International Limited hasobtained conditional approval and orphan drug designation in 2014 forTranslarna, which is a novel gene therapy for the treatment of duchennemuscular dystrophy.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/898
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200 Seattle,WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
